Looking for Company Management? Click here.
Moshe Talpaz, M.D.
Dr. Moshe Talpaz is the Alexander J. Trotman Professor of Leukemia Research, and Associate Division Chief for Hematology at University of Michigan Health System in Ann Arbor. After a postdoctoral fellowship at the University of Texas M. D. Anderson Cancer Center in Houston, Dr. Talpaz joined the faculty of the M. D. Anderson Cancer Center (MDACC) in 1981 as an Assistant Professor of Medicine. He rose in the ranks at MDACC and eventually became the Chairman of the Bioimmunotherapy Department and holder of the David Bruton Chair for Cancer Research before joining the University of Michigan faculty in 2006.
Dr. Talpaz’s academic career has focused on therapeutic developments in Chronic Myeloid Leukemia (CML). He pioneered the development of Interferon therapy for CML and was one of three investigators who conducted the first clinical studies with imatinib (Gleevec), and subsequently with dasatinib (Sprycel), and ponatinib (Iclusig).
Dr. Talpaz has published more than 500 scientific articles and numerous reviews and book chapters. His current research interests are with the study of deubiquitinases (DUBs) and the development of inhibitors to USP9x. He and his research team have been working on this for the last 15 years and have published extensively on the topic.
Hollis Showalter, PhD
Dr. Showalter is a Research Professor of Medicinal Chemistry and co-Director of the Vahlteich Medicinal Chemistry Core. He is the first Director of the University of Michigan Vahlteich Medicinal Chemistry Core (UMVMCC.org), which works with collaborators to advance their drug discovery efforts by selecting appropriate leads from high-throughput screening (HTS) campaigns, contributing synthetic and medicinal chemistry strategies to grant proposals, and developing biological probes or potential therapeutic agents for biological investigation.
Dr. Showalter has published 153 peer reviewed manuscripts/reviews/book chapters, and 150 meeting abstracts. He holds 43 issued or applied for patents and is currently a member of the American Chemical Society Medicinal Chemistry Division Awards Committee.
Nicholas J. Donato, PhD
Dr. Donato is a Research Associate Professor of Internal Medicine Hematology/Oncology at the University of Michigan. He received his B.S. and PhD in Biochemistry from the University of California, Riverside. Following his PhD, Dr. Donato became an NIH Postdoctoral Fellow and then worked for 20 years at the Anderson Hospital and Tumor Institute as a Research Associate.
Matthew Young, PhD
Dr. Young is a Research Assistant Professor of Pharmacology at the University of Michigan. Previously, Dr. Young was an Adjunct Assistant Professor at the Buck Institute for Research on Aging, a Consultant for An2H Discovery, and a Postdoctoral Fellow at the University of California Berkeley and the Rockefeller University. Dr. Young received his B.A. and PhD from Wesleyan University.